Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians.
Looking for a particular Axsome Therapeutics, Inc. employee's phone or email?
Axsome Therapeutics, Inc. Questions
The Axsome Therapeutics, Inc. annual revenue was $385.7 million in 2026.
Herriot Tabuteau is the CEO of Axsome Therapeutics, Inc..
722 people are employed at Axsome Therapeutics, Inc..
Axsome Therapeutics, Inc. is based in New York, New York.
The NAICS codes for Axsome Therapeutics, Inc. are [32541, 325, 32, 3254].
The SIC codes for Axsome Therapeutics, Inc. are [283, 28].
Top Axsome Therapeutics, Inc. Employees
-
34
-
Mark Jacobson
Chief Operating Officer at Axsome Therapeutics, Inc.
New York, NY, US25+ -
Nick Pizzie
Chief Financial Officer at Axsome Therapeutics, Inc.
Franklin Township, NJ, US45 -
Sameer Grover
Associate Vice President at Axsome Therapeutics, Inc.
New York, NY, US45+ -
45+
-
Ari Maizel
Chief Commercial Officer at Axsome Therapeutics, Inc.
Westfield, NJ, US25+ -
Fang Liu
VP, Supply Chain at Axsome Therapeutics, Inc.
Garden City, NY, US24 -
31
Related Companies
